-
1.发明申请METHOD OF EXPRESSING PROTEINS WITH DISULFIDE BRIDGES WITH ENHANCED YIELDS AND ACTIVITY 有权用增强型和活性表达具有不同桥梁的蛋白质的方法公开(公告)号：US20110300579A1
公开(公告)日：2011-12-08
申请号：US13127970
申请日：2009-11-12
Applicant: Radu O. Minea , Stephen D. Swenson , Francis S. Markland, JR.
Inventor： Radu O. Minea , Stephen D. Swenson , Francis S. Markland, JR.
CPC classification number: C12P21/02 , C07K14/46 , C07K2319/35 , C12N9/0036 , C12Y108/01007 , C12Y108/01009
Abstract: Provided herein are methods for expressing proteins with disulfide bridges such as Vicrostatin (VCN), a chimeric variant of native snake venom disintegrin Contortrostatin (CN). The methods include what is believed to be a more efficient natural selection process that results in generating increased amounts of correctly-folded active conformers of proteins with disulfide bridges. In an aspect, this is achieved by growing Origami B cells in a more optimal redox environment during the induction of heterologous recombinant protein production.
Abstract translation: 本文提供了用二硫键表达蛋白质的方法，例如Vicrostatin（VCN），天然蛇毒解嵌合素抗旋转蛋白（CN）的嵌合变体。 这些方法包括被认为是更有效的天然选择过程，其导致蛋白质与二硫键正确折叠的活性构象异构体的量增加。 在一方面，这是通过在诱导异源重组蛋白质生产期间在更优化的氧化还原环境中生长折纸B细胞来实现的。
-
2.发明授权Method of expressing proteins with disulfide bridges with enhanced yields and activity 有权用二硫键表达蛋白质的方法，具有增强的产量和活性公开(公告)号：US08802394B2
公开(公告)日：2014-08-12
申请号：US13127970
申请日：2009-11-12
Applicant: Radu O. Minea , Stephen D. Swenson , Francis S. Markland, Jr.
Inventor： Radu O. Minea , Stephen D. Swenson , Francis S. Markland, Jr.
CPC classification number: C12P21/02 , C07K14/46 , C07K2319/35 , C12N9/0036 , C12Y108/01007 , C12Y108/01009
Abstract: Provided herein are methods for expressing proteins with disulfide bridges such as Vicrostatin (VCN), a chimeric variant of native snake venom disintegrin Contortrostatin (CN). The methods include what is believed to be a more efficient natural selection process that results in generating increased amounts of correctly-folded active conformers of proteins with disulfide bridges. In an aspect, this is achieved by growing Origami B cells in a more optimal redox environment during the induction of heterologous recombinant protein production.
Abstract translation: 本文提供了用二硫键表达蛋白质的方法，例如Vicrostatin（VCN），天然蛇毒解嵌合素抗旋转蛋白（CN）的嵌合变体。 这些方法包括被认为是更有效的天然选择过程，其导致蛋白质与二硫键正确折叠的活性构象异构体的量增加。 在一方面，这是通过在诱导异源重组蛋白质生产期间在更优化的氧化还原环境中生长折纸B细胞来实现的。
-
3.发明申请COMPOSITIONS AND METHODS FOR TREATING OVARIAN CANCER INCLUDING PREVENTING THE RECURRENCE THEREOF 审中-公开用于治疗卵巢癌的组合物和方法，包括预防其复发公开(公告)号：US20160317610A1
公开(公告)日：2016-11-03
申请号：US15080401
申请日：2014-09-25
Applicant: Francis S. MARKLAND, JR. , Stephen D. Swenson , Radu O. Minea
Inventor： Francis S. MARKLAND, JR. , Stephen D. Swenson , Radu O. Minea
Abstract: A method of treating ovarian cancer (OC) includes administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising vicrostatin and/or a protein substantially similar to vicrostatin. The administration is preferably performed intraperitoneally. The methods may include concurrently or sequentially administering to the patient one or more additional treatments for ovarian cancer. A pharmaceutical composition used in connection with the methods of the present invention comprise vicrostatin loaded in a viscoelastic gel comprising polyethylene oxide (PEO) and carboxymethyl cellulose (CMC).
Abstract translation: 治疗卵巢癌（OC）的方法包括向有需要的受试者施用有效量的药物组合物，所述药物组合物包含显微稳态抑制素和/或基本上类似于紫杉醇的蛋白质。 给药优选腹膜内给药。 所述方法可以包括同时或依次向患者施用一次或多次卵巢癌的额外治疗。 用于本发明方法的药物组合物包含负载在包含聚环氧乙烷（PEO）和羧甲基纤维素（CMC）的粘弹性凝胶中的微量抑制剂。
-
4.发明授权Inhibiting integrin receptor binding with non-native monomeric disintegrin or monomeric disintegrin domains 有权抑制整合素受体与非天然单体解体蛋白或单克隆蛋白结合域的结合公开(公告)号：US08338365B2
公开(公告)日：2012-12-25
申请号：US13367267
申请日：2012-02-06
Applicant: Radu O. Minea , Francis S. Markland, Jr.
Inventor： Radu O. Minea , Francis S. Markland, Jr.
CPC classification number: C12P21/00 , A61K38/1703 , C07K14/245 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/90 , C12N9/6418 , C12N9/90 , C12P21/02
Abstract: This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop.
Abstract translation: 本发明涉及抑制一种表达整合素受体特异性的细胞与选自αIIb和bgr; 3，αv＆bgr; 3，αv＆bgr; 5或α5和bgr之间的结合的方法，所述方法包括使细胞与 单体的整合素或单体的整合蛋白结构域，其包含非整数酶解整合素结构域的C-末端序列，所述C-末端序列编码功能性整联蛋白结合环。
-
Patent Agency Ranking
公开(公告)号：US07754850B2
公开(公告)日：2010-07-13
申请号：US11351311
申请日：2006-02-09
Applicant: Radu O. Minea , Francis S. Markland, Jr.
Inventor： Radu O. Minea , Francis S. Markland, Jr.
CPC classification number: C12P21/00 , A61K38/1703 , C07K14/245 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/90 , C12N9/6418 , C12N9/90 , C12P21/02
Abstract: This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.
Abstract translation: 本发明涉及在原核宿主中表达真核蛋白的方法，特别是需要形成用于生物活性的二硫键的真核蛋白。 使用各种方法，包括硫氧还蛋白的融合，二硫键异构酶的细胞质表达，硫氧还蛋白和/或谷胱甘肽还原酶的缺陷，蛋白酶的缺陷等。 该方法适用于表达具有生物学活性的单核和二聚形式的真核生物蛋白，例如单克隆或二聚体形式的解整合素或去整合素结构域。 包括载体，表达蛋白质的宿主细胞，表达的蛋白质和使用蛋白质的方法。
-
6.发明申请INHIBITING INTEGRIN RECEPTOR BINDING WITH NON-NATIVE MONOMERIC DISINTEGRIN OR MONOMERIC DISINTEGRIN DOMAINS 有权抑制与非单因素单核细胞或单个细胞因子结合的INTEGRIN受体结合公开(公告)号：US20120301453A1
公开(公告)日：2012-11-29
申请号：US13367267
申请日：2012-02-06
Applicant: Radu O. Minea , Francis S. Markland, JR.
Inventor： Radu O. Minea , Francis S. Markland, JR.
CPC classification number: C12P21/00 , A61K38/1703 , C07K14/245 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/90 , C12N9/6418 , C12N9/90 , C12P21/02
Abstract: This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop.
Abstract translation: 本发明涉及抑制一种表达整合素受体特异性的细胞与选自αIIb和bgr; 3，αv＆bgr; 3，αv＆bgr; 5或α5和bgr之间的结合的方法，所述方法包括使细胞与 单体的整合素或单体的整合蛋白结构域，其包含非整数酶解整合素结构域的C-末端序列，所述C-末端序列编码功能性整联蛋白结合环。
-
公开(公告)号：US08110542B2
公开(公告)日：2012-02-07
申请号：US12831226
申请日：2010-07-06
Applicant: Radu O. Minea , Francis S. Markland, Jr.
Inventor： Radu O. Minea , Francis S. Markland, Jr.
IPC: A61K38/00 , A61K38/22 , A61K38/36 , C07K14/515 , A61P35/00
CPC classification number: C12P21/00 , A61K38/1703 , C07K14/245 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/90 , C12N9/6418 , C12N9/90 , C12P21/02
Abstract: This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.
Abstract translation: 本发明涉及在原核宿主中表达真核蛋白的方法，特别是需要形成用于生物活性的二硫键的真核蛋白。 使用各种方法，包括硫氧还蛋白的融合，二硫键异构酶的细胞质表达，硫氧还蛋白和/或谷胱甘肽还原酶的缺陷，蛋白酶的缺陷等。 该方法适用于表达具有生物学活性的单核和二聚形式的真核生物蛋白，例如单克隆或二聚体形式的解整合素或去整合素结构域。 包括载体，表达蛋白质的宿主细胞，表达的蛋白质和使用蛋白质的方法。
-
公开(公告)号：US20130045244A1
公开(公告)日：2013-02-21
申请号：US13578551
申请日：2011-02-09
Applicant: Radu O. Minea , Stephen D. Swensen , Francis S. Markland, JR.
Inventor： Radu O. Minea , Stephen D. Swensen , Francis S. Markland, JR.
IPC: C12N9/50 , C12N15/57 , C12N15/62 , C12N15/70 , C12N1/21 , C12N5/071 , G01N33/574 , G01N23/00 , G01N21/64 , C12N11/02 , A61K38/48 , A61P35/00 , A61P35/02 , A61K9/00 , C12N9/96
CPC classification number: C07K14/705 , A61K38/00 , A61L27/34 , A61L27/3679 , A61L27/3834 , C12N9/6489 , C08L89/00
Abstract: Modified ADAM (A Disintegrin and Metalloproteinase) Polypeptides (MAPs) are provided. Methods are provided for administering MAPs for anti-angiogenesis and anti-tumor growth activity. Compositions of the invention are also useful for treating endothelial cell dysfunction and for diagnosis of integrin-related conditions.
Abstract translation: 提供了修饰的ADAM（A整合素和金属蛋白酶）多肽（MAP）。 提供了用于施用抗血管生成和抗肿瘤生长活性的MAP的方法。 本发明的组合物也可用于治疗内皮细胞功能障碍和用于整联蛋白相关病症的诊断。
-
公开(公告)号：US20120142603A1
公开(公告)日：2012-06-07
申请号：US13201433
申请日：2010-02-12
Applicant: Francis S. Markland , Stephen D. Swenson , Radu O. Minea
Inventor： Francis S. Markland , Stephen D. Swenson , Radu O. Minea
IPC: A61K38/02 , C12N5/0797 , C12N5/071
CPC classification number: A61L27/3834 , A61L27/18 , A61L27/227 , A61L27/383 , A61L2400/18 , C08L83/04 , C08L65/04
Abstract: Provided herein are compositions and methods for treating soft tissue injuries using a patch having a polymer on its surface linked to polypeptides having a disintegrin domain. The polypeptides having a disintegrin domain can include contortrostatin, vicrostatin, and ADAM derived polypeptides. Compositions of the invention can be used for the treatment of injuries to soft tissues that include the eye, liver and brain.
Abstract translation: 本文提供了使用其表面上具有聚合物的贴片与具有去整合素结构域的多肽连接的贴片来治疗软组织损伤的组合物和方法。 具有去整合素结构域的多肽可以包括抗雄激素，维生素抑制素和ADAM衍生的多肽。 本发明的组合物可用于治疗包括眼睛，肝脏和脑部的软组织的损伤。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.036 seconds)
